top of page

Expanding the reach of antibody therapeutics​

Determined to revolutionize the reach of cancer treatment by developing potent and precise therapies that can target the entire universe of cancer antigens

Why Crossbow

antibody-2.png

We aim to cure cancer. Our team is urgently working to create an arsenal of therapeutics that expands the reach and impact of antibodies used to treat cancer.​

 ​​

We chose the name Crossbow because our next-generation therapies embody the precision and power of a crossbow. With unparalleled accuracy and potency, our T-Bolt   molecules strike tumor cells like a crossbow shoots bolts at its target.​​

 ​

Join us on our bold quest to broaden the benefits of immunotherapy and improve the lives of people living with cancer.

TM

Science

What we do

slide 3.png

Selecting from the expanding universe of cancer antigens

We identify, validate and prioritize the most promising cancer antigens for our T-Cell Receptor Mimetic (TCRm) discovery efforts​.

Who we are

A team of international, collaborative and experienced inventors, drug developers and company builders. We value scientific excellence, passion, integrity, innovation, transparency, respect and accountability. We embrace problems deemed impossible to solve.

heashots_updated3.png
174857.png
Briggs
Morrison, M.D.

Chief Executive Officer, President

Group 8.png
heashots_updated10.png
174857.png
Michael
Princiotta, Ph.D.

Senior Vice President of Biology

Group 8.png
BenLee-headshot.jpg
174857.png
Benjamin Lee,
M.D., Ph.D.

Senior Vice President, Translational Medicine 

 

Group 8.png
heashots_updated5.png
174857.png
Dmitri
Wiederschain, Ph.D.

Chief Scientific Officer

Group 8.png
heashots_updated2.png
174857.png
Amanda
Mak, Ph.D.

Vice President of Antibody Discovery, Protein Engineering, Process Development

Group 8.png
heashots_updated9.png
174857.png
Jeanne
Freddura, M.S.

Vice President of Finance

Group 8.png
heashots_updated6.png
174857.png
Geraldine
Paulus, Ph.D.

Co-founder, Vice President of Corporate Development and Operations

Group 8.png
heashots_updated4.png
174857.png
Tao
Wang, M.S.

Vice President of Product Discovery, Boston Site Head

Group 8.png
heashots_updated8.2.png
174857.png
Jeanette
Kohlbrenner, M.B.A.

Consulting Head of Human Resources

 

Group 8.png

News & Media

Keep up to date with everything happening at Crossbow

July 11, 2023

​Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance  
a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer

Read More

Contact Us

Thanks for submitting!

bottom of page